RNS Number : 7387C
Iofina PLC
14 June 2023
 

Iofina plc

("Iofina" or the "Company")

(LSE AIM: IOF)

 Results of AGM

Iofina plc, manufacturers of specialty chemical products and specialists in the exploration and production of iodine, held its 2023 Annual General Meeting ("AGM") earlier today.

All resolutions proposed at the AGM, with the exception of resolution 6 (a special resolution for the disapplication of pre-emption rights), as set out in the Notice of Meeting dated 9 May 2023, were duly passed. The Company recognises that a meaningful proportion of votes were cast against resolution 6. Although the resolution was in line with the Company's historic AGM share authorities (all of which have been previously passed), the Board takes seriously its responsibilities to maintain a healthy dialogue with shareholders and will engage with the relevant shareholders to better understand their views.

The full text of the resolutions considered at the AGM are contained in the Notice of AGM which is available on the Company's website at www.iofina.com.

The table below shows the proxy position of all resolutions:

 

RESOLUTIONS

FOR

(and including at discretion)

AGAINST

 

WITHHELD

 

 

Total votes cast: 57,380,461

 

No. of votes

%

No. of votes

%

No. of votes

Resolution 1
To receive and approve the Company's Annual Report and Accounts for the year ended 31 December 2022

57,379,717

99.99%

0

0%

744

Resolution 2

To reappoint Malcolm Lewin as a director

57,254,703

99.78%

95,758

0.17%

30,000

Resolution 3

To reappoint Mary Fallin Christensen as a director

57,344,961

99.93%

5,500

0.01%

30,000

Resolution 4

To reappoint UHY Hacker Young LLP as auditors of the Company and to authorise the directors to determine their remuneration

57,290,088

99.84%

90,373

0.16%

0

Resolution 5

Pursuant to section 551 of the Companies Act 2006 (the "Act"), to unconditionally authorise the Directors to issue shares in the Company

57,336,033

99.92%

35,811

0.06%

8,617

Resolution 6

Disapplication of pre-emption rights. Pursuant to section 570 of the Act, and subject to resolution 5 being passed, to empower Directors to allot shares in the Company without first offering them to existing shareholders on a pro-rata basis

36,498,805

63.61%

20,881,656

36.39%

8,617

Resolution 7

Pursuant to section 701 of the Act, to unconditionally authorise the Company to make market purchases of ordinary shares in the capital of the Company

(representing up to 10% of the issued share capital)

57,325,458

99.90%

37,873

0.07%

17,130

 

Enquiries:

 

Dr. Tom Becker

CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Nomad & Broker:

Henry Fitzgerald-O'Connor/Patrick Dolaghan/Andrew Potts

Canaccord Genuity Limited

Tel: +44 (0)20 7523 8000

 

Financial Adviser:

Kingsley Wilson

Chrystal Capital Partners LLP

Tel: +44 (0)20 7850 4761

 

Media Contact:

Charles Goodwin/Shivantha Thambirajah/Jazmine Clemens

Yellow Jersey PR Limited

Tel: +44 (0)7747 788 221/+44 (0)7983 521 488

 

 

About Iofina:

Iofina plc (AIM:IOF) is a vertically integrated company that specialises in the production of Iodine and the manufacturing of specialty chemical products. Iofina is the second largest producer of iodine in North America and operates the manufacturing entities Iofina Resources and Iofina Chemical.

 

LEI: 213800QDMFYVRJYYTQ84

 

ISIN: GB00B2QL5C79

 

Iofina Resources

Iofina Resources develops, builds, owns, and operates iodine extraction plants using Iofina's WET® IOsorb® technology. Iofina currently operates five producing IOsorb® plants in Oklahoma and is consistently using technology and innovation to improve and expand its operations.

 

Iofina Chemical

Iofina Chemical has manufactured high quality halogen speciality chemicals derived from raw iodine, as well as non-iodine-based products.  Iofina Chemical will be celebrating its 40th anniversary in 2023 as a preeminent halogen-based specialty chemicals company.

 

www.iofina.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGSFDFELEDSELM